TrakCel & McKesson partner to help commercialize gene & cell therapy
By Nikita Chaurasia  Date: 2019-09-13

TrakCel & McKesson partner to help commercialize gene & cell therapy
  • The combination of these two product suites is designed specifically for the growing number of developers that are nearing the commercial launch of gene and cell therapies.
  • The integrated platform allows the product scale-up towards market delivery including automatic product-specific workflow scheduling across multiple care team members and supply chain partners.

McKesson, a leading provider of patient access support, third-party logistic (3PL) services as well as specialty pharmacy solutions, and TrakCel, software developing firm for gene and cell therapy orchestration and supply chain tracking systems, reportedly announced a collaboration to help late-stage developers of gene and cell therapy.

The collaboration will combine both companies’ patient access services and supply chain tracking to allow a more effective path for the industry players to develop next-gen commercial therapies.

Integrating TrakCel’s personalized drug orchestration software and data tracking system with the capabilities of McKesson’s current high-touch platform for patients, as well as both the companies’ support and expertise, will give an end-to-end solution for the gene and cell therapy industry to manage the entirety of the therapeutic supply chain.

McKesson and TrakCel would start by developing a basic solution design. Both these integrated solutions will further be offered to individual company clients which would then benefit specifically from this combined solution.

The combination of these two product suites is particularly designed for the growing number of developers that are approaching commercial launch of their gene and cell therapies. The integrated platform allows the product scale-up towards market delivery.

This also involves automated scheduling of product-centric workflows across numerous care team members and supply chain partners, and a validated tracking of chain-of-identity to ensure delivery of the right drug product. These capabilities guarantee that the patient gets the right, uncompromised treatment at the correct time.

Layne Martin, VP/GM of Specialty Distribution Solutions at McKesson Life Sciences stated that the integrated system would help manufacturers and prescribers work together in a seamless manner to ensure that right patient always gets the right therapeutic product and at the correct time.

Source credit: https://www.businesswire.com/news/home/20190911005059/en/McKesson-TrakCel-Launch-Innovative-Collaboration-Support-Commercialization

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
By Nikita Chaurasia

San Francisco based digital currency exchange major Coinbase has reportedly announced its acquisition of the crypto prime brokerage platform, Tagomi. For eight years, Coinbase has been known for its credibility in the field of industry-leading tradin...

National Congress of China recommends government-led blockchain fund
National Congress of China recommends government-led blockchain fund
By Nikita Chaurasia

The parliament of China, National People’s Congress, has reportedly given a suggestion for a blockchain development fund, backed by the government to be able to build up a good governance system. The most powerful and important political adviso...

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
By Nikita Chaurasia

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial fo...

Researchers to investigate the risk of airborne viruses in buildings
Researchers to investigate the risk of airborne viruses in buildings
By Nikita Chaurasia

As the world gradually paces back to normalcy after recuperating from the devastating effects of COVID-19, a research team from DOE’s Lawrence Berkeley National Laboratory (Berkeley Lab) embarked on the quest to study the risk of airborne virus...

NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
By Nikita Chaurasia

NZME, a News Zealand media giant, has recently unveiled a symbolic US$0.61 (NZ$1) takeover bid for rival Stuff Limited in an attempt for consolidation of the news industry in the country, amid the downturn caused by the coronavirus pandemic. Nine Ent...